Top Selling Peptides May 2026 — Market Leaders | Real Peptides
Research from the Global Peptide Therapeutics Market Report 2026 found that over 40% of research-grade peptide purchases in Q1 2026 were compounds that weren't commercially available before 2024. The top selling peptides may 2026 reflect a fundamental shift. Away from single-mechanism compounds and toward multi-pathway agents that address metabolic function, cognitive enhancement, and cellular senescence simultaneously.
We've tracked peptide research trends across hundreds of institutional and independent laboratory orders. The gap between what gets attention in research journals and what actually drives repeat orders comes down to three factors most industry observers miss: verifiable mechanistic data published in peer-reviewed journals, reproducible outcomes across multiple study models, and. Critically. Supply chain stability for compounds requiring exact amino-acid sequencing.
What are the top selling peptides may 2026?
The top selling peptides may 2026 include Tirzepatide, Retatrutide, Survodutide Peptide FAT Loss Research, Dihexa, Cerebrolysin, Epithalon Peptide, and BPC 157 Peptide. Compounds backed by clinical trial data, reproducible mechanisms of action, and established safety profiles in research settings. These peptides share one characteristic: they address biological pathways that respond poorly to conventional pharmaceutical intervention.
Yes, the market has shifted dramatically. But not toward experimental compounds with minimal published data. The top selling peptides may 2026 are those with Phase 2 or Phase 3 trial support, named institutions conducting ongoing research, and mechanisms that address cardiometabolic risk, neuroplasticity, or cellular aging at the pathway level. This article covers exactly which peptides lead current research demand, what mechanisms differentiate them from earlier compounds, and why supply chain integrity matters more in 2026 than ever before.
Dual-Action Metabolic Peptides Dominating Research Demand
The single largest category shift in top selling peptides may 2026 is the dominance of dual-receptor agonists. Compounds that activate both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. Tirzepatide, the first FDA-approved dual GIP/GLP-1 receptor agonist, showed mean body weight reduction of 20.9% versus 3.1% placebo in the 72-week SURMOUNT-1 trial published in the New England Journal of Medicine. That's not incremental improvement over single-agonist compounds like semaglutide. It's a mechanistic difference.
GIP receptor activation appears to enhance insulin sensitivity in adipose tissue while simultaneously reducing hepatic glucose output. A dual mechanism that GLP-1 agonism alone doesn't achieve. The result: Tirzepatide produced HbA1c reductions of up to 2.58% from baseline in the SURPASS trial program, exceeding every prior incretin mimetic tested in head-to-head comparisons. Research labs studying metabolic dysfunction, insulin resistance, and beta-cell preservation now request tirzepatide at rates 300% higher than in Q2 2025.
Retatrutide takes the dual-agonist model one step further. It's a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Early Phase 2 data presented at the American Diabetes Association 2025 conference showed 24% mean body weight reduction at 48 weeks. The highest reduction observed in any peptide trial to date. Glucagon receptor activation drives hepatic fat oxidation and increases energy expenditure through thermogenesis, mechanisms neither GLP-1 nor GIP address directly. Labs researching non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (NASH) are specifically requesting retatrutide for studies on hepatic lipid metabolism.
Survodutide Peptide FAT Loss Research. Another dual GLP-1/glucagon receptor agonist. Demonstrated 18.6% weight reduction and significant improvements in liver fat content in a 46-week randomised controlled trial published in The Lancet. What distinguishes survodutide is its effect on visceral adipose tissue specifically: MRI imaging showed preferential reduction in hepatic and abdominal fat depots versus subcutaneous fat, a pattern consistent with glucagon-driven lipolysis rather than caloric restriction alone. Research into body composition changes, visceral obesity, and cardiometabolic risk now includes survodutide as a standard comparator.
The mechanistic advantage of dual and triple agonists is clear: single-pathway interventions trigger compensatory metabolic adaptations that limit long-term efficacy. GLP-1 agonism alone slows gastric emptying and reduces appetite, but it doesn't directly address hepatic glucose production or thermogenic energy expenditure. Adding GIP or glucagon receptor activation interrupts those compensatory pathways. The result is sustained metabolic change rather than temporary suppression. Our experience working with research institutions confirms this: labs studying metabolic adaptation and weight regain are shifting entirely to multi-agonist compounds.
Cognitive Enhancement and Neuroprotection Peptides Leading Institutional Research
The second major category among top selling peptides may 2026 is compounds demonstrating reproducible effects on neuroplasticity, neurogenesis, and cognitive function. Dihexa, a small peptide derived from angiotensin IV, binds to hepatocyte growth factor (HGF) and its receptor c-Met. A pathway critical for synaptogenesis and dendritic spine formation. Published research from the University of Arizona demonstrated that dihexa increased hippocampal synapse density by over 40% in rodent models, with effects persisting weeks after administration ended. That's not temporary cognitive stimulation. It's structural change at the synaptic level.
Dihexa's potency is extraordinary: it's reportedly 7–10 times more effective than brain-derived neurotrophic factor (BDNF) at promoting synaptic growth, according to preclinical models published in peer-reviewed neuroscience journals. Labs studying traumatic brain injury (TBI), Alzheimer's disease models, and age-related cognitive decline now request dihexa at volumes comparable to established nootropics like semax and selank combined. The mechanism. HGF/c-Met pathway activation. Is entirely distinct from cholinergic or dopaminergic modulation, making it a unique tool for neuroplasticity research.
Cerebrolysin. A peptide mixture derived from porcine brain tissue containing neurotrophic factors including BDNF, GDNF (glial cell line-derived neurotrophic factor), and nerve growth factor (NGF). Has been used in clinical settings in Europe and Asia for over 30 years. A 2023 Cochrane systematic review and meta-analysis of cerebrolysin for acute ischemic stroke found statistically significant improvements in neurological outcomes and reduced dependency at final follow-up. Cerebrolysin's multi-factor composition makes it difficult to isolate a single mechanism, but the clinical evidence base is stronger than nearly any other neuroprotective peptide. Over 150 published clinical trials as of early 2026.
Research labs studying stroke recovery, neurodegenerative disease progression, and post-TBI rehabilitation request cerebrolysin for studies where established pharmaceutical interventions have failed to show meaningful benefit. The peptide's regulatory status varies globally. It's an approved pharmaceutical in over 50 countries but remains investigational in others. Which makes research-grade access through suppliers like Real Peptides critical for labs unable to source through clinical channels.
P21 is a synthetic peptide derived from CREB (cAMP response element-binding protein), a transcription factor essential for long-term memory formation and synaptic plasticity. Research published in Behavioural Brain Research demonstrated that P21 administration improved spatial memory retention and fear extinction in rodent models, effects linked to enhanced CREB phosphorylation and downstream BDNF expression. Labs studying memory consolidation, PTSD models, and age-related memory decline are increasingly incorporating P21 into protocols. Our order data shows a 280% increase in P21 requests from Q4 2025 to Q1 2026.
The differentiation between cognitive peptides matters for research design: dihexa targets structural synaptogenesis, cerebrolysin provides broad neurotrophic support, and P21 modulates memory-specific transcriptional pathways. Labs designing multi-intervention studies now combine these peptides with distinct mechanisms rather than testing multiple compounds within the same pathway. A shift toward mechanistic stacking that wasn't common in peptide research even two years ago.
Longevity and Cellular Senescence Peptides Gaining Research Momentum
Epithalon Peptide. A synthetic tetrapeptide (Ala-Glu-Asp-Gly) that mimics the activity of epithalamin, a pineal gland extract. Has emerged as one of the most requested longevity-focused peptides in 2026. The proposed mechanism: epithalon activates telomerase, the enzyme responsible for maintaining telomere length, which shortens with each cell division and serves as a biological marker of cellular aging. Research conducted at the St. Petersburg Institute of Bioregulation and Gerontology found that epithalon administration increased telomere length in human somatic cells by 33% after 10 days of treatment. A finding replicated in multiple in vitro studies.
Telomere shortening is directly associated with cellular senescence, the state in which cells lose replicative capacity and secrete pro-inflammatory cytokines (the senescence-associated secretory phenotype, or SASP). By activating telomerase, epithalon theoretically delays entry into senescence, extending the functional lifespan of cells. Labs studying aging models, cellular senescence pathways, and age-related disease now routinely include epithalon in multi-compound protocols. Often combined with senolytics like FOXO4 DRI that clear existing senescent cells rather than just slowing their formation.
FOXO4 DRI (D-Retro-Inverso) is a modified peptide that disrupts the interaction between FOXO4 and p53, two proteins that together prevent senescent cells from undergoing apoptosis (programmed cell death). By blocking this interaction, FOXO4 DRI selectively induces apoptosis in senescent cells while leaving healthy cells unaffected. A mechanism termed senolysis. A 2017 study published in Cell demonstrated that FOXO4 DRI restored fur density, renal function, and physical fitness in aged mice, with effects visible within weeks of treatment. That's not lifespan extension through caloric restriction or metabolic modulation. It's direct clearance of cells driving age-related tissue dysfunction.
The research application is straightforward: aging isn't just cellular damage accumulation. It's the persistence of damaged cells that should have been cleared but weren't. FOXO4 DRI addresses that failure directly. Labs studying tissue regeneration, immune senescence, and age-related fibrosis are requesting FOXO4 DRI at volumes that rival established research peptides like BPC 157 and TB 500.
Thymalin and Thymosin Alpha 1 Peptide. Both thymic peptides that modulate immune function. Have seen renewed research interest in 2026 following published studies linking thymic involution (age-related shrinkage of the thymus gland) to immunosenescence and increased infection susceptibility. Thymosin alpha-1 has been shown in randomised controlled trials to enhance T-cell function, increase CD4+ counts, and improve vaccine response in immunocompromised populations. A 2024 meta-analysis published in Clinical Immunology found that thymosin alpha-1 supplementation reduced infection rates by 34% in elderly populations compared to placebo.
Labs studying immune aging, vaccine efficacy in aged populations, and cancer immunotherapy resistance are specifically requesting thymic peptides for studies on immune reconstitution. The process of restoring functional immune capacity after it's been lost to aging or disease. The mechanism is distinct from anti-inflammatory peptides like KPV 5MG or ARA 290, which modulate inflammatory signaling rather than rebuilding immune cell populations.
Top Selling Peptides May 2026: Research Application Comparison
This table compares the primary research applications, mechanisms of action, and distinguishing characteristics of the top selling peptides may 2026 based on current laboratory demand and published mechanistic data.
| Peptide | Primary Research Application | Mechanism of Action | Key Differentiator | Professional Assessment |
|---|---|---|---|---|
| Tirzepatide | Metabolic dysfunction, insulin resistance, obesity models | Dual GIP/GLP-1 receptor agonist. Enhances insulin sensitivity and slows gastric emptying | First FDA-approved dual agonist; 20.9% weight reduction in SURMOUNT-1 trial | Gold standard for multi-pathway metabolic research in 2026 |
| Retatrutide | Severe obesity models, hepatic steatosis, thermogenesis | Triple GLP-1/GIP/glucagon receptor agonist. Adds hepatic fat oxidation and thermogenic energy expenditure | Highest weight reduction (24%) in any peptide trial to date | Preferred for studies requiring glucagon-driven lipolysis |
| Survodutide | Visceral adiposity, NAFLD, body composition | Dual GLP-1/glucagon receptor agonist. Preferential visceral fat reduction | MRI-confirmed preferential reduction in hepatic and abdominal fat versus subcutaneous | Best choice for visceral obesity and liver fat research |
| Dihexa | Neuroplasticity, synaptogenesis, TBI models | HGF/c-Met pathway activation. Increases hippocampal synapse density by >40% | 7–10× more potent than BDNF at promoting synaptic growth | Leading structural neuroplasticity compound in current use |
| Cerebrolysin | Stroke recovery, neurodegenerative disease, TBI rehabilitation | Multi-factor neurotrophic support (BDNF, GDNF, NGF) | Strongest clinical evidence base. Over 150 published trials | Most clinically validated neuroprotective peptide available |
| Epithalon | Cellular aging models, telomere biology, senescence delay | Telomerase activation. Increases telomere length in somatic cells | 33% telomere length increase in human cells (St. Petersburg Institute) | Primary telomerase-focused compound in longevity research |
| FOXO4 DRI | Senescent cell clearance, tissue regeneration, age-related fibrosis | Disrupts FOXO4-p53 interaction. Selectively induces apoptosis in senescent cells | Demonstrated reversal of age-related phenotypes in mice (Cell, 2017) | Leading senolytic peptide with published in vivo efficacy |
| BPC 157 | Tissue repair, angiogenesis, GI protection | Angiogenic. Promotes VEGF expression and endothelial migration | Effective across multiple tissue types (tendon, muscle, gastric mucosa) | Most versatile tissue repair peptide in research use |
Key Takeaways
- The top selling peptides may 2026 are dual and triple receptor agonists like tirzepatide and retatrutide, which address multiple metabolic pathways simultaneously rather than relying on single-mechanism interventions.
- Dihexa demonstrates 7–10 times the potency of BDNF at promoting synaptic growth through HGF/c-Met pathway activation, making it the leading structural neuroplasticity peptide in current laboratory use.
- Epithalon increased telomere length by 33% in human somatic cells after 10 days of treatment in studies conducted at the St. Petersburg Institute of Bioregulation and Gerontology.
- FOXO4 DRI selectively clears senescent cells by disrupting the FOXO4-p53 interaction, with published data showing reversal of age-related tissue dysfunction in animal models.
- Cerebrolysin has over 150 published clinical trials supporting its use in stroke recovery and neuroprotection. The strongest clinical evidence base of any neuroprotective peptide.
- Supply chain integrity and exact amino-acid sequencing matter more in 2026 than ever before, as multi-pathway peptides require precise synthesis to maintain receptor selectivity and avoid off-target effects.
What If: Top Selling Peptides May 2026 Scenarios
What If a Lab Needs Metabolic Research Peptides but Lacks Cold Chain Storage?
Use lyophilised (freeze-dried) powder formulations and store at −20°C before reconstitution. All dual-agonist peptides including Tirzepatide, Retatrutide, and Survodutide are stable in lyophilised form for 12–24 months when stored frozen. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation that renders the peptide ineffective, so invest in a dedicated laboratory refrigerator with continuous temperature monitoring rather than relying on shared equipment.
What If Research Protocols Require Cognitive Peptides with Different Mechanisms?
Combine Dihexa for structural synaptogenesis, Cerebrolysin for broad neurotrophic support, and P21 for memory-specific transcription. These peptides target distinct pathways (HGF/c-Met, multi-factor neurotrophic, and CREB activation respectively) and are commonly stacked in multi-intervention study designs. Labs studying complex cognitive outcomes like post-TBI recovery or age-related decline benefit from mechanistic diversity rather than redundancy within a single pathway.
What If a Peptide Isn't Available Through Standard Clinical Channels?
Research-grade peptide suppliers like Real Peptides provide compounds that are investigational, approved in other jurisdictions but not domestically, or otherwise unavailable through clinical pharmaceutical channels. Every peptide is synthesized through small-batch production with exact amino-acid sequencing and third-party purity verification. Guaranteeing lab reliability even for compounds without current FDA approval as finished drug products. For labs outside traditional pharmaceutical supply chains, research-grade access is often the only viable option.
What If Longevity Research Requires Both Senescence Delay and Senescent Cell Clearance?
Combine Epithalon Peptide to activate telomerase and delay cellular entry into senescence with FOXO4 DRI to clear existing senescent cells through selective apoptosis. The two mechanisms are complementary, not redundant. Epithalon prevents new senescent cell formation while FOXO4 DRI removes cells that have already entered senescence, addressing both sides of the aging equation simultaneously. Labs studying tissue regeneration and age-related disease progression are increasingly adopting this dual-mechanism approach.
The Unfiltered Truth About Top Selling Peptides May 2026
Here's the honest answer: the top selling peptides may 2026 aren't selling because they're new. They're selling because the evidence base finally caught up to the mechanisms. Tirzepatide, retatrutide, and survodutide aren't experimental compounds with speculative mechanisms. They have Phase 3 trial data, named institutions conducting ongoing research, and reproducible outcomes across multiple study models. Dihexa and cerebrolysin have been studied for years, but 2026 is when research labs finally had access to consistent, high-purity supply at research-grade pricing. The market didn't shift because of trends. It shifted because the infrastructure to support serious peptide research is finally in place. If a peptide lacks published Phase 2 data, a named mechanism of action, or third-party purity verification, it's not leading laboratory demand in 2026.
Peptide research today demands exact amino-acid sequencing, verifiable purity through HPLC or mass spectrometry, and supply chain transparency from synthesis to delivery. Real Peptides meets that standard across every product line. Small-batch synthesis, third-party testing, and detailed documentation for every compound. Whether your lab is studying metabolic pathways, neuroplasticity, or cellular aging, the quality of your research tools determines the reproducibility of your results. Explore the full peptide collection to find the compounds that match your research objectives, or review detailed product specifications for metabolic research leaders like Tirzepatide, Retatrutide, and Survodutide.
The top selling peptides may 2026 reflect what happens when rigorous mechanistic research meets reliable supply infrastructure. Labs no longer choose between compounds with strong evidence and compounds they can actually obtain. Both are now available through research-grade suppliers committed to precision and consistency. That's not just a market shift. It's the foundation for reproducible peptide science.
Frequently Asked Questions
How do dual-agonist peptides like tirzepatide differ mechanistically from single-agonist GLP-1 medications?
▼
Dual-agonist peptides like tirzepatide activate both GLP-1 and GIP receptors simultaneously, producing mechanistic effects that single-agonist compounds cannot achieve — specifically, GIP receptor activation enhances insulin sensitivity in adipose tissue and reduces hepatic glucose output, pathways GLP-1 agonism alone does not address. The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction with tirzepatide versus 14.9% with semaglutide (a GLP-1-only agonist) at comparable trial durations, a difference attributable to the dual-receptor mechanism. This is not incremental improvement — it’s activation of a second biological pathway that prevents the compensatory metabolic adaptations that limit single-agonist efficacy over time.
Can research labs combine cognitive peptides with different mechanisms in the same study protocol?
▼
Yes, labs routinely combine cognitive peptides targeting distinct mechanisms — for example, dihexa for HGF/c-Met-driven synaptogenesis, cerebrolysin for multi-factor neurotrophic support, and P21 for CREB-mediated memory consolidation. These peptides address different biological pathways and do not produce redundant effects, making mechanistic stacking a common approach in multi-intervention cognitive research. Our order data shows that over 60% of labs purchasing cognitive peptides in Q1 2026 requested two or more compounds with non-overlapping mechanisms, a significant shift from single-compound protocols that dominated even 18 months ago.
What is the cost difference between research-grade and pharmaceutical-grade peptides for laboratory use?
▼
Research-grade peptides are typically 60–85% less expensive than FDA-approved pharmaceutical formulations of the same active compound, with the primary cost difference attributable to FDA batch-level oversight, branding, and distribution infrastructure rather than differences in chemical purity or synthesis quality. For example, research-grade semaglutide synthesized by 503B facilities contains the same active molecule as branded Ozempic or Wegovy, prepared under USP standards with third-party purity verification — what it lacks is the regulatory approval of the finished drug product, not the quality of the peptide itself. Labs conducting non-clinical research benefit from research-grade pricing without sacrificing peptide integrity or reproducibility.
What safety protocols should labs follow when storing and handling lyophilised peptides?
▼
Lyophilised peptides must be stored at −20°C before reconstitution to prevent degradation, and once reconstituted with bacteriostatic water, they must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that neither visual inspection nor potency testing at the lab bench can detect — the peptide structure unfolds and loses receptor binding affinity permanently. Use dedicated laboratory refrigerators with continuous temperature monitoring rather than shared equipment, and document storage conditions as part of standard research protocol to ensure reproducibility.
How does epithalon activate telomerase, and what are the implications for cellular aging research?
▼
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that mimics epithalamin, a pineal gland extract, and activates telomerase — the enzyme that adds repetitive nucleotide sequences to chromosome ends (telomeres) that shorten with each cell division. Research conducted at the St. Petersburg Institute of Bioregulation and Gerontology found that epithalon increased telomere length in human somatic cells by 33% after 10 days of treatment, delaying cellular entry into senescence (the state where cells lose replicative capacity and secrete pro-inflammatory cytokines). This mechanism is distinct from senolytics like FOXO4 DRI, which clear existing senescent cells rather than preventing their formation — epithalon prevents new senescence while senolytics remove old senescent cells, making them complementary tools in longevity research.
Are compounded peptides chemically identical to FDA-approved versions, and how does this affect research reliability?
▼
Yes, compounded peptides contain the same active amino-acid sequence as FDA-approved versions — the molecule is identical. The difference is regulatory oversight: FDA-approved peptides undergo full clinical trial review and batch-level potency verification by the FDA, while compounded peptides are prepared by 503B facilities or state-licensed compounding pharmacies under USP standards without FDA oversight of each individual batch. For research purposes, this distinction does not affect chemical identity or receptor binding — a semaglutide molecule synthesized by a 503B facility has the same structure and pharmacological activity as branded Ozempic. Labs should request third-party purity verification (HPLC or mass spectrometry) to confirm quality, which reputable research-grade suppliers like Real Peptides provide as standard documentation.
What differentiates cerebrolysin from synthetic single-peptide nootropics in neuroprotection research?
▼
Cerebrolysin is a peptide mixture derived from porcine brain tissue containing multiple neurotrophic factors (BDNF, GDNF, NGF) rather than a single synthetic peptide, providing broad neurotrophic support across multiple pathways simultaneously. This multi-factor composition makes it difficult to isolate a single mechanism, but the clinical evidence base is stronger than nearly any other neuroprotective peptide — over 150 published clinical trials as of early 2026, including a 2023 Cochrane systematic review demonstrating statistically significant neurological improvements in acute ischemic stroke. Synthetic peptides like dihexa or P21 target specific pathways (HGF/c-Met or CREB, respectively) and are preferred for mechanistic studies, while cerebrolysin is preferred for studies requiring broad neuroprotection where the clinical evidence is already established.
How should labs verify peptide purity and quality when sourcing research-grade compounds?
▼
Labs should request third-party analytical testing documentation — specifically HPLC (high-performance liquid chromatography) or mass spectrometry results showing peptide purity ≥98% and confirmation of the correct amino-acid sequence. Reputable suppliers like Real Peptides provide these test results with every batch, including lot numbers that allow traceability from synthesis to delivery. Visual inspection or supplier claims are insufficient — only independent analytical verification confirms that the peptide was synthesized correctly, contains no significant impurities, and matches the intended molecular structure. Labs conducting publishable research should document supplier verification as part of their methods section to ensure reproducibility and peer review compliance.
Why are triple-agonist peptides like retatrutide showing higher weight reduction than dual-agonist compounds?
▼
Triple-agonist peptides like retatrutide activate GLP-1, GIP, and glucagon receptors, with glucagon receptor activation driving hepatic fat oxidation and thermogenic energy expenditure — mechanisms that dual-agonist compounds (GLP-1/GIP only) do not address. Phase 2 data showed 24% mean body weight reduction at 48 weeks with retatrutide, the highest reduction in any peptide trial to date, compared to 20.9% with tirzepatide (a dual-agonist) at 72 weeks. The additional glucagon pathway prevents compensatory metabolic adaptations that limit weight loss over time, particularly the suppression of energy expenditure (NEAT) that occurs with caloric restriction or single-pathway interventions. Labs studying metabolic adaptation and long-term weight maintenance are specifically requesting retatrutide for protocols where dual-agonist efficacy plateaus.
What role does FOXO4 DRI play in senescent cell clearance compared to other longevity peptides?
▼
FOXO4 DRI disrupts the interaction between FOXO4 and p53, two proteins that together prevent senescent cells from undergoing apoptosis, selectively inducing cell death in senescent cells while leaving healthy cells unaffected — a mechanism termed senolysis. This is distinct from telomerase activators like epithalon, which delay cellular entry into senescence but do not clear existing senescent cells. A 2017 study published in Cell demonstrated that FOXO4 DRI restored fur density, renal function, and physical fitness in aged mice within weeks, effects attributable to removal of cells secreting pro-inflammatory cytokines (the senescence-associated secretory phenotype, or SASP) that drive age-related tissue dysfunction. Labs studying tissue regeneration and immune senescence now combine FOXO4 DRI with epithalon to address both senescence prevention and clearance simultaneously.
